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The networks of blood and lymphatic vessels and of the extracellularmatrix and their cellular
and structural components, that are collectively termed the tumor microenvironment,
are frequently co-opted and shaped by cancer cells to survive, invade, and form distant
metastasis. With an enviable capacity to adapt to continually changing environments,
cancer represents the epitome of functional chaos, a stark contrast to the hierarchical
and organized differentiation processes that dictate the development and life of biological
organisms. The consequences of changing landscapes such as hypoxia and acidic
extracellular pH in and around tumors create a cascade of changes in multiple pathways
and networks that become apparent only several years later as recurrence and metastasis.
These molecular and phenotypic changes, several of which are mediated by COX-2,
approach the complexities of a “Gordian Knot.”We review evidence from our studies and
from literature suggesting that cyclooxygenase-2 (COX-2) biology presents a nodal point in
cancer biology and an “Achilles heel” of COX-2-dependent tumors.
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INFLAMMATION IN THE TUMOR MICROENVIRONMENT
Hostile physiological environments such as hypoxia and acidic
extracellular pH which exist in solid tumors, as well as envi-
ronments created by conventional therapy such as radiation,
chemotherapy, and surgery, may promote invasion and metas-
tasis through inﬂammatory responses and the formation of
eicosanoids. As outlined in the schematic in Figure 1, the
characteristic response of living vascularized tissue to injury is
inﬂammation, which induces the formation of eicosanoids. Three
classes of phospholipases (PLs) A2, C, and D, participate in the
formation of free arachidonic acid (AA) from membrane phos-
pholipids in response to mechanical, chemical, and physical
stimuli (Kaiser et al., 1990). Since AA is derived from membrane
phospholipids, its production and utilization in the formation of
eicosanoids is closely coupled to membrane choline phospholipid
metabolism (Kaiser et al., 1990). In response to pro-inﬂammatory
cytokines AA is converted to various eicosanoids by the action
of cytochrome P450 enzymes, lipoxygenases, and cyclooxygenases
(COX; Needleman et al., 1986; Haeggstrom et al., 2010; Greene
et al., 2011). These eicosanoids impact cell motility, invasion,
vascular characteristics, and metastatic dissemination (Fulton,
1988; Liu et al., 2010; Menter et al., 2010). Most solid tumors,
including breast cancers, exhibit inﬂammatory properties char-
acterized by increased levels of prostaglandins (PGs) and other
pro-inﬂammatorymolecules that are secreted by tumor cells, stro-
mal cells, and specialized immune cells during inﬂammation, with
nuclear factor kappaB (NF-κB) considered as a central molecu-
lar mediator of these responses (DiDonato et al., 2012). Such an
upregulation of inﬂammatory characteristics is not surprising in
viewof the similarities betweenphysiological conditions in injured
tissue, such as hypoxia and low extracellular pH, and the physio-
logical environment of solid tumors (Gillies et al., 2000). Unlike
lung and colon, where the source of inﬂammatory signaling as
an instigator of, and contributor to, tumorigenesis is obvious,
the breast has long been thought of as lacking such extrinsic
inﬂammatory stimuli. Epidemiological studies however, have long
showed a link between obesity and breast cancer (Gilbert and
Slingerland, 2013). Adipose tissue, abundant in the human breast,
has been shown to secrete pro-inﬂammatory cytokines, termed
adipokines, capable of producing low-grade chronic inﬂamma-
tion in the human breast (Ouchi et al., 2011; Baumgarten and
Frasor, 2012).
COX-2 IN BASIC, TRANSLATIONAL, AND CLINICAL BREAST
CANCER RESEARCH
COX-1 and COX-2 are cytoplasmic enzymes that convert PLA2-
mobilizedAA into the lipid signal transductionmolecules PGs and
thromboxanes (TXs; van der Donk et al., 2002). One major prod-
uct of the COX-2-catalyzed reaction is PGE2, an inﬂammatory
mediator participating in several biological processes, includ-
ing development, pain, immunity, angiogenesis (Smith et al.,
2000), and cancer (Howe, 2007; Singh-Ranger et al., 2008). Studies
examining the expression of COX-2 using immunohistochemistry
concluded that COX-2 expression is observed in approximately
42% of breast cancers (Glover et al., 2011). COX-2 function has
been the target of pharmaceutical intervention in a multitude of
widespread degenerating conditions, including autoimmune dis-
eases, gastric inﬂammation, and several different cancers, such
as colon, gastric, breast, and lung cancer (Koehne and Dubois,
2004; Xu et al., 2004; Wallace, 2005; Wang et al., 2005; Diaz-Cruz
and Brueggemeier, 2006; Krysan et al., 2006). Its expression is
induced by pro-inﬂammatory cytokines, such as interleukin (IL)-
1β and tumor necrosis factor (TNF)-α, and its promoter contains
a cyclic AMP response element, a NF-κB binding site, and a
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FIGURE 1 |The cyclooxygenase pathway. In response to
pro-inﬂammatory stimuli COX-2 is expressed in the cytoplasm
of many cell types where it catalyzes the conversion of arachidonic
acid to prostaglandins and thromboxanes. PL, phospholipase; NSAID,
non-steroidal anti-inﬂammatory drugs; coxibs, COX-2-selective
inhibitors; COX, cyclooxygenase; PG, prostaglandin; TX,
thromboxane; PTGIS, prostacyclin synthase; PGES, prostaglandin
synthase.
nuclear factor for interleukin-6/CCAAT enhancer-binding protein
(NF-IL6/C/EBP) sequence (Chun and Surh, 2004).
The utility of COX-2 as a target for cancer treatment has been
debated for decades and the ﬁrst clinical trials using COX-2-
selective inhibitors for cancer treatment tookplace in the late 1990s
when celecoxib was shown to reduce colon adenomas in patients
with familial adenomatous polyposis (FAP; Steinbach et al., 2000).
Soon thereafter, celecoxib was shown to reduce polyp formation in
sporadic colorectal adenocarcinomas (Arber et al., 2006; Bertag-
nolli et al., 2006), butwith increased risk of death by cardiovascular
complications (Baron et al., 2008; Solomonet al., 2008). As a result,
celecoxib use for cancer prevention was limited to FAP patients.
Results from clinical trials using celecoxib alone suggested a mod-
est effect of celecoxib in primary breast cancer (Martin et al.,
2010). Studies using celecoxib in combination with aromatase
inhibitors were either terminated early due to cardiovascular side
effects (Falandry et al., 2009) or showed no signiﬁcant differ-
ence in the response rate with the inclusion of celecoxib (Chow
et al., 2008). The cardiovascular side effects observed following
prolonged celecoxib administration were attributed to an imbal-
ance of eicosanoid production toward the pro-thrombotic TXA2
(Antman et al., 2007). The limited responses to celecoxib cou-
pled with the signiﬁcant cardiovascular side effects have resulted
in a signiﬁcant shift in focus to downstream targets such as PG
synthases and receptors. Initially, it was reasoned that celecoxib
has many COX-2-independent functions that are responsible for
its anti-tumorigenic effects (Grosch et al., 2006) and that, given
the cardiotoxicity associated with COX-2 inhibition, the COX-2-
independent anti-tumorigenic effects of coxibs needed to be
pursued further. Attempts to reduce inﬂammation using anti-
inﬂammatory celecoxib analogs designed to not bind to COX-2
and display anti-tumor and anti-inﬂammatory properties have
shown some promise (Schonthal et al., 2008).
Despite the discordance between the promise of basic studies
and the limited clinical beneﬁts of coxibs, several observations
favor COX-2 as a target for cancer treatment. First, targeting path-
ways downstream of COX-2 is likely to dilute the effect of COX-2
inhibition, since the COX reaction is the rate-limiting enzyme of
prostanoid formation (Samuelsson et al., 1978). Second, there is
compelling evidence obtained by studying the effects of COX-2
using short interfering RNA (siRNA) or using the exogenous sup-
plementation of COX-2 reaction products demonstrating that
COX-2 promotes carcinogenesis and metastasis. Such evidence
is discussed below and in the references cited. Third, TXA2
synthase inhibitors given concurrently with COX-2 inhibitors
could alleviate the cardiovascular side effects attributed to the
inhibition of COX-2 by coxibs. A more detailed review of the
risks and rewards of targeting COX-2 in cancer was recently
published (Menter et al., 2010). Fourth, the limited beneﬁts of
celecoxib in human subjects can be explained by the observa-
tion that many of the coxib-associated effects observed in vitro
and in vivo are not related to COX-2 inhibition, but to COX-2-
independent actions of coxibs (Grosch et al., 2006; Schonthal et al.,
2008). Fifth, not all tumors or metastatic processes are COX-2-
dependent and the expression of a highly inducible enzyme
such as COX-2 does not necessarily suggest critical function in
every instance it is observed. Thus the utilization of COX-2
inhibitors, even if they speciﬁcally inhibited COX-2 function,
would not be beneﬁcial until primary tumors and metastatic
processes that had a signiﬁcant requirement for COX-2 were tar-
geted. It would thus be of clinical beneﬁt to discover biomarkers
that reﬂect the activity of COX-2 in tumors and in the tumor
microenvironment.
COX-2 EXPRESSION AND CLINICAL OUTCOMES IN BREAST
CANCER
Several studies have sought to correlate the expression of COX-2
with existing clinical markers in breast cancer. Recently, a large
study (n = 1162) of biomarker expression in ductal carcinoma
in situ (DCIS) was published (Kerlikowske et al., 2010) where it
was shown that the diagnosis of breast tumors by palpitation or
the concurrent triple expression of p16/COX-2/Ki67 signiﬁed an
increased risk of recurrence of invasive breast cancer 8 years fol-
lowing initial diagnosis and lumpectomy. A separate study of 248
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cases of breast cancer showed that COX-2 expression was ele-
vated in hormone receptor (HR) negative or human epidermal
growth factor receptor 2 (HER2) positive subpopulations and cor-
related with an activation of the oncogene Akt and with poor
survival (Glover et al., 2011). Others, however, demonstrated that
COX-2 expression correlates with poor outcomes independently
of the expression of established markers of breast cancer (Kim
et al., 2012). In addition, COX-2 expression has been demon-
strated across all clinically useful categories of breast cancers
suggesting that COX-2 expression is not predominantly related
to hormone or HER2 receptor status. Further complicating the
retroﬁtting of COX-2 positivity within established breast cancer
subtypes is the fact that COX-2 expression and function may
originate fromnon-epithelial cellular components of themicroen-
vironment such as the immune response, or the tissue response
to injury. Correlative studies that attempt to stratify the expres-
sion of COX-2 within current types of breast cancer would miss
the transient inﬂuence of microenvironment-derived COX-2. It
is our view that the discovery of biomarkers that predict the
mechanistic association of breast tumor initiation, progression,
and metastasis with COX-2 function, can only be attained by
the employment of high-throughput/omics approaches on a vari-
ety of constituent and representative cells that are engineered
to over- or under-express COX-2. The objective would be to
derive tumor-promoting COX-2-associated molecular signatures
that can be correlated with aggressive phenotypes in experi-
mental animal models and validated in sample tissue or sera of
patients.
COX-2 INDUCES THE EXPRESSION OF ONCOGENES BY
CO-OPTING BIOLOGICAL EFFECTORS OF HYPOXIA AND
DEVELOPMENT
Given the pleiotropic effects of COX-2 products during devel-
opment, physiology and disease we have sought to investigate
whether COX-2 represents a Gordian knot or an Achilles heel
in breast cancer by utilizing COX-2-speciﬁc siRNA in a cell-based
model of tumor growth andmetastasis (summarized in Figure 2).
We have observed increased expression of COX-2, in several,
but not all, triple negative human breast cancer cells that were
also metastatic (unpublished observations). We silenced COX-2
in the most metastatic breast cancer cells and observed a pro-
found decrease of metastasis and tumor onset in vivo, although
cell proliferation rates were unaffected in culture (Stasinopoulos
et al., 2007). Interactions between the cancer cell and the tumor
microenvironment (TME) following COX-2 silencing became
apparent in functional imaging assays that revealed a signiﬁcant
decrease of invasion into reconstituted extracellular matrix (ECM;
Stasinopoulos et al., 2007; Shah et al., 2012), an altered interac-
tion between endothelial cells and cancer cells following COX-2
silencing (Stasinopoulos et al., 2008), and a signiﬁcant alteration in
glycolysis, pH, and cholinemetabolism (Stasinopoulos et al., 2008;
Shah et al., 2012). The associations between COX-2 and choline
metabolism, glycolysis and pHhave identiﬁed new functional roles
of COX-2 that may reveal new biomarkers and new targets to use
in combination with COX-2 targeting.
The activation of several genes that form the adaptive
response of cells to hypoxia is mediated through the binding of
hypoxia-inducible factor (HIF)-1 to the hypoxia response ele-
ments that regulate the transcription of these genes (Maxwell
et al., 1997). Under oxygenated conditions HIF-1α is rapidly
degraded, but under hypoxic conditions HIF-1α is stabilized (Liu
and Semenza, 2007). We examined differences in the hypoxia and
inﬂammation-driven functional activation of HIF-1α in COX-
2-expressing and COX-2-silenced cells, and found that COX-2
is important for IL-1β, but not hypoxia-driven, HIF-1α stabi-
lization and induction of HIF-1α target genes (Stasinopoulos
et al., 2009). These data imply that PGE2 can employ the tran-
scription factor HIF-1, and the multitude of HIF-1 responsive
genes, to promote malignant phenotypes associated with HIF-
1 activation such as drug resistance, increased invasion, and
altered metabolism (Semenza, 2012; Shay and Simon, 2012) even
underwell-oxygenated conditions. Choline kinase (Chk), aHIF-1-
regulated (Glunde et al., 2008) cytoplasmic enzyme responsible for
the phosphorylation of choline to phosphocholine (PC) involved
in invasion and metastasis (Glunde et al., 2011), was also down-
regulated in COX-2-silenced cells (Shah et al., 2012), suggesting
a possible mechanism of regulation of phospholipid metabolism
by the COX-2-HIF-1 axis. Our results are compatible with a study
showing that IL-1-mediatedHIF-1 stabilization via COX-2 upreg-
ulation and NF-κB activation in lung and colon cancer cells (Jung
et al., 2003). Cancers with a strong inﬂammatory component will
most likely have functional HIF-1α activation even under nor-
moxic conditions; targeting COX-2 could minimize these effects.
Several insults to tissue such as reactive oxygen species, ioniz-
ing radiation, and physical trauma during surgery are known
stimuli for the initiation or exacerbation of the inﬂammatory
response (Molla and Panes, 2007; Rundhaug and Fischer, 2008).
Peri-operative administration of the COX-2 inhibitor etodolac is
being investigated in clinical trial NCT00502684. Our data sup-
port the administration of anti-inﬂammatory agents immediately
following surgery and ionizing radiation treatment of patients to
minimize activation of the IL-1β–COX-2–HIF-1α axis of onco-
genic signaling. This topic has been extensively discussed elsewhere
(Choy and Milas, 2003; Imtiyaz and Simon, 2010). Transcrip-
tome analysis revealed differential expression of genes that control
angiogenesis, invasion, and differentiation including the wnt/β-
catenin pathway (Stasinopoulos et al., 2012). These changes will
identify candidate reporter elements in the promoter of these genes
that can be used to image the induction of COX-2 expression.
Loss of COX-2 resulted in the loss of lymphoid enhancer-binding
factor-1 (LEF-1) mRNA, and nuclear LEF-1 protein, while exoge-
nous supplementation of PGE2 restored nuclear LEF-1 levels
in COX-2-silenced cells (Stasinopoulos et al., 2012). Since LEF-
1 is a transcription factor that mediates Wnt signaling during
development and disease, these results are consistent with the
demonstration that PGE2 can promote non-canonicalWnt signal-
ing by directing the translocation of β-catenin from the cytoplasm
to the nucleus of colon cancer cells (Castellone et al., 2005). The
induction of LEF-1 and the stabilization of HIF-1α by COX-2 pro-
vide additional examples of the co-option of molecular pathways
central to the response to injury and development by tumors. In
addition to providing important cues regarding the role of COX-
2 in breast cancer, transcriptome analysis of COX-2-silenced and
COX-2 containing cells has indicated candidate reporter elements
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FIGURE 2 | COX-2, Gordian knot or Achilles heel? (A)
Physiological processes with signiﬁcant COX-2 involvement.
(B) COX-2 silencing changes the metabolic proﬁle of breast cancer
cells to a less aggressive phenotype. (C) COX-2 silencing reduces
the invasiveness of breast cancer cell. (D) COX-2 silencing
abolishes the extrapulmonary colonization of metastatic breast
cancer cells. (E) Sites of primary tumors with extensive COX-2
involvement.
in the promoters of these genes that can be used to image the
function of COX-2 in vivo.
SILENCING OF COX-2 INHIBITS METASTASIS AND DELAYS
TUMOR ONSET OF POORLY DIFFERENTIATED METASTATIC
BREAST CANCER CELLS
Breast cancer cells silenced for the expression of COX-2 using
stable expression of short hairpin RNA were less able to invade
reconstituted ECMthanparental cells in vitro (Stasinopoulos et al.,
2007). MDA-MB-231 cells silenced for COX-2 expression showed
reduced mRNA expression of several oncogenic markers, includ-
ing IL-11, a marker for metastasis of breast cancer to bone, the
Notch1 receptor ligand JAG1, whose expression is correlated with
poor breast cancer prognosis, CXCR4, a receptor involved in can-
cer cell invasion, and matrix metalloproteinase-1 (MMP-1), a
secreted enzyme responsible for the degradation of the stroma
during breast cancer cell invasion. Dynamic tracking of invasion
and metabolism of COX-2-silenced intact MDA-MB-231 cells,
using our magnetic resonance (MR) compatible cell perfusion
apparatus, under controlled pH, temperature, and oxygenation
over 48 h, revealed signiﬁcantly reduced levels of total choline, PC,
and lactate compared to parental MDA-MB-231 cells (Figure 2B)
and reduced invasion (Figure 2C). These changes also correlated
with a reduction of Chk levels in COX-2-silenced cells (Shah et al.,
2012). The metabolic changes are consistent with a less aggres-
sive phenotype since PC and total choline, as well as Chk, are
biomarkers of malignancy (Glunde et al., 2011).
Loss of COX-2 resulted in the signiﬁcant delay of tumor onset
when the cellswere injected in themammary fat padof severe com-
bined immunodeﬁcient (SCID) mice (Stasinopoulos et al., 2007)
consistent with the observation that COX-2 was found to be a part
of a gene signature that predicted metastasis of MDA-MB-231
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cells to the lung (Gupta et al., 2007). Silencing of COX-2 resulted
in the inhibition of metastasis to the lungs of SCID mice after
intravenous injection (Stasinopoulos et al., 2007) and Figure 2D.
Our results show that COX-2 expressionmodulates the expression
or function of many ECM components, including collagen, gly-
coproteins [e.g., thrombospondin-1 (THBS-1)], hyaluronan, and
proteoglycans (e.g., lumican). It is possible that tumor-derived
COX-2 modiﬁes the ECM enabling tumors to successfully estab-
lish metastases. The role of COX-2 and COX-2-produced PGs
in promoting cancer cell adhesion in the ECM has recently been
reviewed elsewhere (Menter and Dubois, 2012). Additionally, evi-
dence that COX-2 inhibition reduces collagen deposition, tumor
growth, and invasion during mammary gland involution was
recently described (Lyons et al., 2011). While this model specif-
ically addressed the increasing risk of breast cancer following
pregnancy, the association of collagen deposition and remodel-
ing with breast cancer metastasis is under investigation (Schedin
and Keely, 2011). It was recently shown that increased collagen
content correlated with metastasis to lymph nodes (Kakkad et al.,
2012). Alignment of collagen ﬁbers perpendicularly to the tumor
boundary was associated with decreased disease-free survival in
breast cancer patients (Conklin et al., 2011). Further studies are
needed to understand the role of COX-2 in the ECM remodel-
ing during normal development and disease. Modiﬁcation of the
ECMbymicroenvironment-derived COX-2 could also explain the
observation that tissues with active inﬂammatory processes, such
as wounds, are sites of frequently successful metastases. These data
strongly support investigating the relationship between COX-2
and the structure and function of the ECM further.
THE MALIGNANT PHENOTYPE OF BREAST CANCER CELLS IS
REDUCED BY COX-2 SILENCING
COX-2 silencing resulted in the loss of expression of metabolic
symporters, ECM components, and several proangiogenic fac-
tors (Stasinopoulos et al., 2008). Our data implicate COX-2 as a
regulator of processes central to tumor metabolism, angiogen-
esis, and ECM composition, making it a major contributor to
a microenvironment permissive to tumorigenesis, invasion, and
metastasis. In these functional studies, silencingCOX-2 expression
resulted in a decrease of lactate production or export, a decrease
in medium acidiﬁcation, a decrease in the secretion of the ECM
component hyaluronan, and an inhibition of human umbilical
vein endothelial cell (HUVEC) network formation (Stasinopoulos
et al., 2008). Extracellular lactate concentration and extracellular
acidiﬁcation were reduced in COX-2-silenced cells. Microar-
ray results from COX-2-expressing and COX-2-silenced cells
revealed alterations in transcripts regulating glutamate transport
(SLC1A1) as well as other glycolysis-related transporters and
enzymes involved in cancer progression such as hexokinase II.
COX-2-silenced MDA-MB-231 cells actively inhibited HUVEC
network formation when co-cultured on an ECM gel suggesting
that COX-2 plays an important role in angiogenesis, a process
essential for primary and metastatic tumor growth (Potente et al.,
2011). Transcriptome comparisons between COX-2-expressing
and COX-2-silenced cells revealed changes in several angiogen-
esis related transcripts such as CXCR4 (Stasinopoulos et al., 2007)
conﬁrmed at the protein level (Stasinopoulos et al., 2008). CXCR4
is a chemokine receptor important in cancer cell invasion and
angiogenesis and has been shown to be regulated by COX-2 and
PGE2 levels in Lewis lung carcinoma cells (Katoh et al., 2010).
The loss of several proangiogenic factors may explain the inability
of HUVEC to form networks and self-associate and the marked
reduction in orthotopic tumor growth. COX-2nullmice that over-
expressed a HER2/neu transgene under the control of the mouse
mammary tumor virus promoter, showed reduced tumor mul-
tiplicity and size compared to COX-2 expressing mice, but also
demonstrated reduced vasculature in non-tumormammary tissue
(Howe, 2007). Conversely, forced COX-2 expression in the mam-
mary gland of mice increased microvascular density, which was
reversed by treatment with celecoxib (Chang et al., 2004). Many
COX-2 reaction products have been implicated in angiogenesis
including TXA2, PGI2, and PGE2 (Pradono et al., 2002; Chang
et al., 2004; Obermajer et al., 2011). Imaging the COX reaction
directly, or indirectly through the effects of the COX-2 prod-
ucts in vivo, is ideally compatible with identifying mechanisms
employed by COX-2-dependent tumors, and identifying markers
of COX-2-promoted angiogenesis and metastasis.
CONCLUSION
Molecular characterization and functional imaging have identi-
ﬁed new functional roles for COX-2, creating new possibilities for
more effective COX-2 targeting, and for imaging COX-2 expres-
sion and activity. Our results are presented within the context
of the function of COX-2-related biology and disease in Figure 1.
Here we have highlighted the importance of targeting this pathway
in cancer, and establishing strategies to image COX-2 expression
and activity.
These studies emphasize the importance of expanding our
understanding of the role of COX-2 in altering the tumor pheno-
type and of non-invasively identifying tumors that have increased
COX-2 expression and functionality, to select for COX-2 targeting.
The answer to the question posed in this title cannot be decided
until COX-2-dependent tumor initiation, growth, or metasta-
sis is identiﬁed and inhibited in vivo using novel and improved
approaches.
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